Atelerix Life Sciences
Atelerix Life Sciences is dedicated to developing novel respiratory therapies to address urgent unmet medical needs in respiratory diseases and bio-defense. The company is focused on advancing multiple pre-clinical and clinical-stage therapies, including ATLX-0199, a novel respiratory stimulant for drug-induced respiratory depression (DIRD) and related conditions. Their mission is to lead scientific research that will change clinical practice and save lives, especially in critical care and surgical settings.
Industries
Nr. of Employees
small (1-50)
Atelerix Life Sciences
1800 N Capitol Ave Noyes Pavilion, 5th Floor, Suite E504-ATLX Indianapolis, IN 46202
Products
Lead small-molecule respiratory stimulant (development-stage prodrug)
A development-stage prodrug small molecule designed to stimulate respiratory drive without antagonizing opioid analgesia; converts in red blood cells to an active moiety that modulates ion-channel pathways governing respiration.
Lead small-molecule respiratory stimulant (development-stage prodrug)
A development-stage prodrug small molecule designed to stimulate respiratory drive without antagonizing opioid analgesia; converts in red blood cells to an active moiety that modulates ion-channel pathways governing respiration.
Services
Preclinical studies, toxicology, and regulatory documentation preparation to support IND submission and early-phase clinical testing.
Production of GMP-compliant drug product for use in clinical studies and regulatory testing.
In vivo studies measuring ventilation, arterial blood gas chemistry, and antinociception to evaluate efficacy and safety of respiratory-stimulant candidates.
Preclinical studies, toxicology, and regulatory documentation preparation to support IND submission and early-phase clinical testing.
Production of GMP-compliant drug product for use in clinical studies and regulatory testing.
In vivo studies measuring ventilation, arterial blood gas chemistry, and antinociception to evaluate efficacy and safety of respiratory-stimulant candidates.
Expertise Areas
- Small-molecule drug discovery
- Preclinical respiratory pharmacology
- Mechanism-of-action studies (ion channel modulation)
- IND-enabling development and regulatory strategy
Key Technologies
- Active thiol-based small molecules
- Prodrug design with red blood cell-mediated activation
- Voltage-gated potassium channel modulation
- In vivo respiratory physiology assays
News & Updates
Atelerix Life Sciences received a contract from BARDA to support the first-in-human clinical trial of ATLX-0199, a novel respiratory stimulant for respiratory depression.
A study published in Scientific Reports shows ATLX-0199 reverses morphine’s effects on breathing while augmenting pain relief.
Atelerix Life Sciences received a contract from BARDA to support the first-in-human clinical trial of ATLX-0199, a novel respiratory stimulant for respiratory depression.
A study published in Scientific Reports shows ATLX-0199 reverses morphine’s effects on breathing while augmenting pain relief.